World journal of gastroenterology · 2014
Expression of alpha smooth muscle actin in living donor liver transplant recipients.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hirabaru Masataka, Mochizuki Kyoko, Takatsuki Mitsuhisa, Soyama Akihiko, Kosaka Taiichiro, Kuroki Tamotsu, Shimokawa Isao, Eguchi Susumu
Аннотация
Recently, there have been reports from liver biopsies that showed the progression of liver fibrosis in liver transplant patients after the cessation of immunosuppression. Herein, we focused on activated hepatic stellate cells expressing alpha smooth muscle actin (α-SMA) to understand the correlation between immunosuppressant medication and liver fibrosis. The study enrolled two pediatric patients who underwent living donor liver transplantation and ceased immunosuppressant therapy. The number of α-SMA-positive cells in the specimens obtained by liver biopsy from these two patients showed a three-fold increase compared with the number from four transplanted pediatric patients who were continuing immunosuppressant therapy. In addition, the α-SMA-positive area evaluated using the WinRooF image processing software program continued to increase over time in three adult transplanted patients with liver fibrosis, and the α-SMA-positive area was increasing even during the pre-fibrotic stage in these adult cases, according to a retrospective review. Therefore, α-SMA could be a useful marker for the detection of early stage fibrosis.
Предметные рубрики MeSH
ActinsBiliary AtresiaBiomarkersBiopsyChildChild, PreschoolDrug Administration ScheduleEarly DiagnosisFemaleHepatic Stellate CellsHumansImage Interpretation, Computer-AssistedImmunohistochemistryImmunosuppressive AgentsInfantLiver CirrhosisLiver TransplantationLiving DonorsMalePredictive Value of TestsRetrospective StudiesRisk FactorsTime FactorsTransplant RecipientsTreatment Outcome